Key statistics
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 30.61m |
Free float | 29.23m |
P/E (TTM) | -- |
Market cap | 2.52bn USD |
EPS (TTM) | -1.11 USD |
--
More ▼
Announcements
- Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
- Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results
- Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds
- Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
- Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit
- Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease
- Belite Bio to Participate in Three Upcoming Investor Conferences
- Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
- Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
- Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
More ▼